Key result
High-dose elamipretide decreased left ventricular end-diastolic volume and end-systolic volume compared with placebo.
Why the study?
Does a single infusion of elamipretide improve cardiac structure and function and is it safe in patients with heart failure with reduced ejection fraction?
RCT (n=36)
Double-blind
randomized
Does a single infusion of elamipretide improve cardiac structure and function and is it safe in patients with heart failure with reduced ejection fraction?
Answers are grounded in this paper and cite their sources.
A single infusion of the novel mitochondria-targeting peptide elamipretide is safe and acutely reduces left ventricular volumes in patients with HFrEF.
Background Mitochondrial dysfunction and energy depletion in the failing heart are innovative therapeutic targets in heart failure management. Elamipretide is a novel tetrapeptide that increases mitochondrial energy; however, its safety, tolerability, and therapeutic effect on cardiac structure and function have not been studied in heart failure with reduced ejection fraction. Methods and Results In this double-blind, placebo-controlled, ascending-dose trial, patients with heart failure with reduced ejection fraction (ejection fraction, ≤35%) were randomized to either a single 4-hour infusion of elamipretide (cohort 1 [n=8], 0.005; cohort 2 [n=8], 0.05; and cohort 3 [n=8], 0.25 mg·kg −1 ·h −1 ) or placebo control (n=12). Safety and efficacy were assessed by clinical, laboratory, and echocardiographic assessments performed at pre-, mid- and end-infusion and 6-, 8-, 12- and 24-hours postinfusion start. Peak plasma concentrations of elamipretide occurred at end-infusion and were undetectable by 24 hours postinfusion. There were no serious adverse events. Blood pressure and heart rate remained stable in all cohorts. Compared with placebo, a significant decrease in left ventricular end-diastolic volume (−18 mL; P =0.009) and end-systolic volume (−14 mL; P =0.005) occurred at end infusion in the highest dose cohort. Conclusions This is the first study to evaluate elamipretide in heart failure with reduced ejection fraction and demonstrates that a single infusion of elamipretide is safe and well tolerated. High-dose elamipretide resulted in favorable changes in left ventricular volumes that correlated with peak plasma concentrations, supporting a temporal association and dose–effect relationship. Further study of elamipretide is needed to determine long-term safety and efficacy. Clinical Trial Registration URL: https://www.clinicaltrials.gov . Unique identifier: NCT02388464.
No takes yet. Share an insight, caveat, or question.
Daubert et al. (2017) conducted an RCT in Heart failure with reduced ejection fraction (n=36). Elamipretide vs. Placebo was evaluated on Left ventricular end-diastolic volume and end-systolic volume (MD -18 mL for LVEDV, -14 mL for LVESV, p=0.009 for LVEDV, 0.005 for LVESV). High-dose elamipretide decreased left ventricular end-diastolic volume and end-systolic volume compared with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: